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Abstract 
Although apoptosis plays a critical role in molding the CNS into its final appearance and 
function, inappropriate activation of this pathway in the aging brain may contribute to 
neurodegeneration. In Alzheimer’s disease (AD), an overwhelming body of evidence 
supports the activation of apoptosis in general, and caspases specifically as an early event 
that may not only contribute to neurodegeneration but also promote the underlying 
pathology associated with this disease. Therefore, caspase inhibitors may provide an 
effective strategy for treating AD. However, despite the compelling evidence indicating a 
role for caspases in disease progression, chronic treatment with caspase inhibitors in animal 
models of AD has never been undertaken. In this review the role of caspases in AD will be 
addressed, including recent studies utilizing in vivo transgenic mouse models of 
tauopathies. In addition, a discussion of the therapeutic value and dangers of targeting 
caspase inhibition in the treatment of AD using caspase inhibitors such as Q-VD-OPh will 
be evaluated. 
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Overview of Alzheimer’s Disease 
 
Recent statistics in the United States regarding Alzheimer’s disease (AD) are alarming: 5.3 million people have AD 
with a new case diagnosed every 70 seconds and AD is currently the sixth leading cause of death [1]. AD is a 
progressive neurodegenerative disorder characterized by confusion, disturbances in short-term memory and 
cognitive impairment. These early symptoms of AD may be overlooked because they resemble signs of natural 
aging. As the disease progresses, the symptoms gradually worsen until patients lose the ability to feed themselves, 
speak, recognize people and memory becomes almost non-existent. In addition, during the advanced stages of 
dementia, the impact on the lives of patients and their caregivers is enormous. 
 
Pathologically, AD is a progressive neurodegenerative disorder characterized by significant losses of neurons and 
synapses [2]. Diagnosis is based on the extent of accumulation of senile plaques, neurofibrillary tangles (NFTs), and 
neuron loss [3]. NFTs consist of paired helical filaments (PHF) resulting from the hyper-phosphorylation of the 
microtubule-binding protein tau. As a microtubule-associated protein, tau plays an essential role in maintaining 
microtubule stability similar to ties along railroad tracks. However, in AD neuronal tau is aberrantly phosphorylated 
and proteolyzed resulting in an impairment of the normal functions of tau [4, 5]. Besides NFTs, the other 
troublemakers are senile plaques composed principally of extracellular amyloid-  (A ) depositions. A  is formed 
following sequential cleavage of the amyloid precursor protein (APP) by two proteases termed - and -secretases. 
Following generation, A  self-aggregates into insoluble -sheet structures leading to the formation of extracellular 
plaques. The deposition of A  is an early event in the pathogenesis of AD that precedes the formation of NFTs and 
collectively is referred to as the “beta-amyloid hypothesis” [6]. More recently, the beta-amyloid hypothesis has been 
extended by suggesting that A - oligomers, due to their central neuropathologic role, are the major causative  
species for the development of AD [7]. The extension of the beta-amyloid hypothesis to include A  oligomers is 
based at least in part on the poor correlation between the number of senile plaques and cognitive decline [8]. Figure 
1b depicts the characteristic pathology associated with AD, with an abundance of both plaques and tangles present 
in one representative brain region, the hippocampus. Interestingly, a smattering of tangles can also be observed in 
the age-matched non-demented control subject (arrow, Fig. 1a). The finding of NFTs in non-demented aging 
subjects is a well-documented finding (for example, see [9]), and suggests that the presence of a small number of 
NFTs in vulnerable brain regions doesn’t not necessary imply neurodegeneration or disease. Although the presence 
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of both plaques and tangles is a central feature associated with AD, the link connecting these two hallmark 
pathologies has remained elusive. Recent evidence suggests that caspase activation and cleavage of tau may link 
plaques and tangles in AD. 
 
Caspase activation and cleavage of tau in the AD brain 
 
Our interest in the role of caspases in Alzheimer’s began almost 10 years ago when we began investigating 
apoptosis as a cell death mechanism in the AD brain. At the time there was support for apoptosis as a major cell-
death pathway in the AD brain [10], however, this was greatly disputed because the major technique to detect 
apoptosis, TUNEL labeling, was deemed nonspecific [11]. Therefore, we sought to examine a role for apoptosis in 
the AD brain utilizing caspase-cleavage site-directed antibodies. In this approach, antibodies are directed towards 
the active fragments of caspases or neoepitope regions of caspase substrates following cleavage. This approach was 
first employed by Yang el al. who, using a site-directed antibody to caspasecleaved actin, was able to demonstrate 
convincingly the activation of apoptotic pathways in the AD brain [12]. This was followed by a comprehensive 
study by Gervais et al., in which a site-directed caspase-cleavage antibody to APP demonstrated labeling in the AD 
brain and suggested that not only was APP a substrate for caspases but cleavage may facilitate the further production 
of the toxic A fragment [13]. Based on these studies, we applied the same approach to design a specific site-
directed antibody to fodrin, a major cytoskeletal protein expressed in neurons [14]. Application of this antibody 
showed widespread caspase-cleaved fodrin in the AD brain [15]. An interesting outcome from that study was the 
apparent correlation between caspase-cleaved fodrin and NFTs [15]. It was concluded that perhaps there was a link 
between caspase activation and the formation of NFTs in the AD brain. Another piece of evidence suggesting that 
caspases may link A  to NFTs in AD was the identification that tau is a major substrate for caspase cleavage, in 
vitro [16]. Canu et al. were able to show that there were three potential caspase cleavage sites within tau, and based 
on this study, we designed a caspase-cleavage site-directed antibody to the amino-terminal site within tau. Following 
characterization of this antibody, we were able to demonstrate immunolabeling of this antibody in the AD brain that 
was absent in age-matched nondemented control subjects [17]. This was the first demonstration of the presence of 
caspase-cleaved tau in AD. Following this study, we developed a hypothesis in which A  triggers the activation of 
caspases leading to proteolysis of tau and the NFT formation[18]. 
 
Shortly thereafter, two studies largely confirmed our hypothesis by demonstrating that the caspase cleavage of tau is 
an early event in NFT evolution, and links A  to NFT formation in the AD brain [19, 20]. Both studies relied 
heavily on data obtained using identical site-directed antibodies to the C-terminal caspase-cleavage site within tau 
located at amino acid residue D421. Both studies supported a general role for caspase-3 as being the major 
executioner protease involved in cleaving tau at this C-terminal site. In addition to caspase-3, strong evidence for 
caspase-6 and the cleavage of tau in the AD brain has been demonstrated [21], suggesting the cooperation of 
multiple members of the caspase family in the proteolysis of tau. Importantly, the use of postmortem human AD 
tissue in these studies makes it difficult to determine a direct relationship between the caspase-cleavage of tau and 
the formation of NFTs. Figure 2 summarizes the data supporting a role for caspase activation as being one link 
between A  and NFT formation in the AD brain. 
 
More recently, transgenic mice studies have provide additional evidence that caspases play a proximal role in 
promoting tangle formation in AD. We utilized the 3xTg-AD mice developed by Oddo et al. to examine more 
directly the role for caspases in tangle formation. 3xTg-AD mice sequentially form A
alterations including hyperphosphorylation that closely models what occurs in the human AD brain [22, 23]. We 
generated 3xTg-AD mice that overexpress the anti-apoptotic protein, Bcl-2, specifically in neurons of the CNS and 
aged the mice accordingly before behavioral and pathological examination. It was determined that overexpression of 
Bcl-2 prevented caspase activation and cleavage of tau, limited the degree of tau hyperphosphorylation, and 
improved spatial memory [24]. Even more convincing then this study, are the recent studies coming out of Bradley 
Hyman’s group using multiphoton microscopy, a technique that allows one to detect caspase activation in the living 
brain and follow this activation over several days. Using this powerful technique, Spires-Jones et al. were able to 
detect active caspases within tangle-bearing neurons in the rTg4510 mouse model of tauopathy [25]. They have been 
able to extend these findings by showing that even though caspases are activated with NFT-bearing neurons, these 
neurons do not immediately die, but exhibit significant loss of membrane integrity as indicated by the presence 
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of propidium iodide labeling [26]. Taken together, these studies employing animal models of AD provide strong 
experimental support for a role in caspases in the etiology associated with AD, and thus, are potential therapeutic 
targets for the treatment of this disease. 
 
Caspases as Therapeutic Targets in the Treatment of AD 
 
The potential for caspase inhibitors as therapeutic agents is not unique to AD. Indeed, for many years caspase 
inhibitors such as N-benzyloxycarbonyl-Val-Ala-Asp fluoromethyl-ketone (Z-VAD) were being investigated for the 
treatment of a number of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS) [27], 
Huntington’s disease [28], Parkinson’s disease (PD) [29], and finally acute neurologic diseases including ischemia 
or traumatic injury (for review, see [30]). Unfortunately, clinical development of Z-VAD was discontinued 
following the recognition that metabolism of Z-VAD produces liver damage following the production of the toxic 
compound, fluoroacetate [31]. 
 
Following the disappointment of Z-VAD, a number of other caspase inhibitors have been developed with the goal in 
mind of being safer and more selective. Quinolyl-valyl-Omethylaspartyl-[- 2, 6-difluorophenoxy]-methyl ketone (Q-
VD-OPh) is a newer, third-generation broad-spectrum caspase inhibitor that has potential as a therapeutic compound 
[32]. Q-VD-OPh appears to be far superior to Z-VAD in many respects including greater potency, selectivity, 
stability and cell permeability [32]. Q-VD-OPh also appears to be less toxic than Z-VAD even at very high 
concentrations [33]. Most importantly, Q-VD-OPh appears to be able to cross the blood-brain barrier, which is 
always a central issue when developing a drug for treatment of a CNS disorder. Evidence for neuroprotection 
included studies demonstrating efficacy of Q-VDOPh in animal models of Parkinson’s, Huntington’s disease and 
stroke [34, 35]. Therefore, QVD-OPh would seem to be an ideal candidate to test whether pharmacological 
inhibition of caspases in vivo can prevent the pathology associated with AD. The critical next step is to test directly 
whether Q-VD-OPh prevents neurodegeneration or other aspects of pathology using animal models of AD. 
 
Another promising compound that is currently under evaluation is minocycline, a second-generation tetracycline. In 
comparison to Q-VD-OPh, minocycline is much further along as an investigational drug for the treatment of 
neurodegenerative disorders and in some cases human clinical trials have begun. For example, minocycline is 
currently being tested in a Phase II PD clinical trial as well as a Phase I/II clinical trial for spinal cord injury (for a 
recent review, see [36]). In addition, recently a Phase III trail involving minocycline as a therapeutic agent for the 
treatment of ALS was completed. Unfortunately, the results of the trial were negative as the authors found that 
patients on minocycline declined at a more rapid rate than the placebo group [37]. These results are disappointing 
and certainly will have implications for potential future clinical trials of minocycline in AD. Nonetheless, there is 
ample data to suggest minocycline may be a suitable treatment option for AD. In one study by Choi et al., the 
authors reported that minocycline administration improved behavior deficits in A  infused rats [38]. Minocycline 
also has been shown to improve behavioral deficits while reducing the level of microglial activation in a mouse of 
model cerebral microvascular amyloid, although there was no apparent reduction in A
another study using transgenic mice harboring the human APPsw and V717F mutations, treatment with minocycline 
had a positive effect on reducing microglial activation but did not attenuate A
APP mice [40]. Younger mice faired better, exhibiting improved behavioral and microglial suppression following 
minocycline treatment [40]. Finally, a recent study showed that in primary cortical neurons minocycline prevented 
A -induced death, caspase-3 activation, and reduced the levels of caspase-cleaved tau [41]. The same authors 
showed that in vivo treatment of transgenic mice overexpressing human tau with minocycline reduced levels of tau 
phosphorylation and tau cleavage by caspase-3 [41]. Taken together, these studies support a preventative effect of 
minocycline on caspase activation, pathological changes to tau and the inflammation associated with AD with little 
effect on A  deposition. This suggests that the mechanism of action of minocycline may lie downstream to A  
production and deposition. 
 
Mechanistically, current data suggests minocycline inhibits apoptosis by preventing the release of cytochrome c 
from mitochondria and subsequent caspase-3 activation [42, 43], although how minocycline is actually  
accomplishing this feat is presently unknown. Minocycline also exhibits strong anti-inflammatory actions 
particularly in preventing reactive microgliosis [44, 45] a key feature that has been associated with AD [46]. 
Therefore, minocycline would seem an ideal compound to be tested in the treatment of AD based partly on its 
putative mechanisms of action. Table 1 summarizes the similarities and differences between Q-VD-OPh and 
minocycline with regards to their potential as therapeutic agents for the treatment of AD. 
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Possible toxicities associated with caspase inhibitors as treatment compounds for AD 
 
An obvious point of concern of utilizing caspase inhibitors such as Q-VD-OPh in the treatment of AD are potential 
toxicities related to the inhibition of apoptosis in other cell types. Chronic administration of any caspase inhibitor for 
a time period exceeding 14 days has never been reported in any animal model or in vivo disease system. Clearly, one 
might predict the deleterious effects of a non-selective caspase inhibitor, given the important role of caspases in 
overall tissue homeostasis. However, based on available evidence, Q-VD-OPh and other caspase inhibitors may 
have a more limited toxicity profile than predicted. First, Chauvier et al., found that after acute treatment of Q-VD-
OPh in mice, all organs were normal suggesting a lack of toxicity [33]. Second, the caspase inhibitor IDN-6556, 
which shares structural similarities with Q-VD-OPh, was reported to be safe and well tolerated in humans (up to 10 
mg/kg/infusion for a single dose) in a phase I clinical trial [47]. This was a 14-day study in which there were no 
apparent drug-related adverse events. Third, the potential for a lack of toxicity by Q-VD-OPh could be predicted 
based on the fact that caspase inhibitors cannot block any caspase-independent cell death pathways. Similar to IDN-
6556, minocycline has a proven track record for safety in a number of clinical trials involving humans. For example, 
treatment with minocycline in Phase I clinical trials for ALS and PD has been successfully completed with little 
toxicity noted (reviewed in [36]). However, in a recent Phase III trial, patients on minocycline declined more 
quickly than those on placebo [37]. In addition, a Phase II trial for PD indicated a decrease tolerability of 
minocycline in the treatment group [48]. It should be noted that differences in toxicity between minocycline and Q-
VD-OPh may be expected if one considers the multiplicity of putative actions of minocycline versus Q-VD-OPh, 
which is extremely selective for only inhibiting caspases. In sum, the potential for toxicity and untoward side effects 
with caspase inhibitors is an obvious concern. Until comprehensive studies with caspase inhibitors, such as Q-VD-
OPh are carried out in animal models of AD one can only speculate on the relative efficacy versus toxicity that may 
occur following chronic treatment. 
 
Conclusions 
 
Mounting evidence suggests the involvement of caspases in the disease process associated with AD. The activation 
of caspases may be responsible for the neurodegeneration associated with AD and several recent studies have 
suggested that caspases may also play a role in promoting the disease mechanisms associated with this disease. 
Thus, caspase activation and cleavage of critical cellular proteins associated with AD pathology may facilitate both 
the production of A  as well as the formation of NFTs. Because the activation of caspases in AD may be a proximal 
event that is not just associated with neurodegeneration, caspases are potential therapeutic targets for the treatment 
of this disorder. Presently, there are only a few FDA-approved medications available for patients afflicted with AD 
and these medications are palliative in nature. Although there are numerous strategies under development that 
involve the beta-amyloid hypothesis, it is still not known whether these strategies will positively impact the disease. 
Given the recent phase III clinical trial failures involving the beta-amyloid hypothesis [49], a prudent approach to 
developing therapeutics for AD should be aimed at other potential targets. Over a decade of research has supported a 
role for the activation of caspases in the AD brain, and recent studies has indicated an involvement in this pathway 
in promoting the pathology underlying this disease. However, to date, studies testing the potential of anti-apoptotic 
compounds have yet to be realized. This may be partly due to real concerns related to potential side effects 
associated with the chronic treatment of apoptotic inhibitors including most importantly, the potential for tumor 
formation. Two compounds, minocycline and Q-VD-OPh, seem ideal candidates to test in animal models of AD. 
Until studies in animal models of AD are carried out, we will never know whether the risk/reward associated with 
caspase inhibitors such as Q-VD-OPh are worthy of future drug development for the treatment of AD. With the 
number of Americans with Alzheimer’s expected to triple by the middle of the century [1], the risk of testing 
apoptotic inhibitors as a treatment strategy seems well worth the effort. 
 
 
 
 
 
 
 
 
 
 
4
 
 
This is an author-produced, peer-reviewed version of this article.  The final publication is available at www.springerlink.com. Copyright 
restrictions may apply.  DOI: 10.1007/s10495-010-0463-2 
References Cited 
 
1. (2009) Alzheimer's disease facts and figures. Alzheimers Dement 5:234-270. 
 
2. Duyckaerts C, Delatour B, Potier MC. (2009) Classification and basic pathology of Alzheimer disease. Acta 
Neuropathol 118:5-36. 
 
3. Mirra SS, Heyman A, McKeel D, et al. (1991) The consortium to establish a registry for Alzheimer's disease 
(CERAD) part II. Standardization of the neuropathological assessment of 
Alzheimer's disease. Neurol 41:479-486. 
 
4. Trojanowski JQ, Schmidt ML, Shin R-W, Bramblett GT, Goedert M, Lee M-Y. (1993) From pathological marker 
to potential mediator of neuronal dysfunction and degeneration in Alzheimer's disease. Clinical Neuroscience 1:184-
191. 
 
5. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. (1993) Abnormal tau phosphorylation 
at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 
10:1089-1099. 
 
6. Golde TE, Dickson D, Hutton M. (2006) Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. 
Curr Alzheimer Res 3:421-430. 
 
7. Lambert MP, Barlow AK, Chromy BA, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are 
potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453. 
 
8. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. (1992) Neurofibrillary tangles but not senile plaques 
parallel duration and severity of Alzheimer's disease. Neurology 42:631-639. 
 
9. Price JL, Morris JC. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. 
Ann Neurol 45:358-368.  
 
10. Su JH, Anderson AJ, Cummings BJ, Cotman CW. (1994) Immunohistochemical evidence for DNA 
fragmentation in neurons in the AD brain. Neuroreport 5:2529-2533. 
 
11. Charriaut-Marlangue C, Ben-Ari Y. (1995) A cautionary note on the use of the TUNEL stain to determine 
apoptosis. Neuroreport 7:61-64. 
 
12. Yang F, Sun X, Beech W, et al. (1998) Antibody to caspase-cleaved actin detects apoptosis in differentiated 
neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease (see comments). Am J Pathol 
152:379-389. 
 
13. Gervais FG, Xu D, Robertson GS, et al. (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's 
amyloid- beta precursor protein and amyloidogenic A beta peptide formation. Cell 97:395-406. 
 
14. Goodman SR, Zagon IS, Coleman DB, McLaughlin PJ. (1986) Spectrin expression inneuroblastoma cells. Brain 
Res Bull 16:597-602. 
 
15. Rohn TT, Head E, Su JH, et al. (2001) Correlation between caspase activation and neurofibrillary tangle 
formation in Alzheimer's disease. Am J Pathol 158:189-198. 
 
16. Canu N, Dus L, Barbato C, et al. (1998) Tau cleavage and dephosphorylation in cerebellar granule neurons 
undergoing apoptosis. J Neurosci 18:7061-7074. 
 
17. Rohn TT, Rissman RA, Davis MC, Kim Y-E, Cotman C, Head E. (2002) Caspase-9 Activation and caspase 
cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11:341-354. 
 
5
 
 
This is an author-produced, peer-reviewed version of this article.  The final publication is available at www.springerlink.com. Copyright 
restrictions may apply.  DOI: 10.1007/s10495-010-0463-2 
18. Rohn TT, Rissman RA, Head E, Cotman CW. (2002) Caspase activation in the Alzheimer's disease brain: 
tortuous and torturous. Drug News Perspect 15:549-557. 
 
19. Gamblin TC, Chen F, Zambrano A, et al. (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary 
tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100:10032-10037. 
 
20. Rissman RA, Poon WW, Blurton-Jones M, et al. (2004) Caspase-cleavage of tau is an early event in Alzheimer 
disease tangle pathology. J Clin Invest 114:121-130. 
 
21. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. (2004) Active caspase-6 and caspase-6-
cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 
165:523-531. 
 
22. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. (2003) Amyloid deposition precedes tangle 
formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24:1063-1070. 
 
23. Oddo S, Caccamo A, Shepherd JD, et al. (2003) Triple-transgenic model of Alzheimer's 
disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409- 
421. 
24. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E. (2008) Lack of pathology in a triple 
transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci 
28:3051-3059. 
 
25. Spires-Jones TL, de Calignon A, Matsui T, et al. (2008) In vivo imaging reveals dissociation between caspase 
activation and acute neuronal death in tangle-bearing neurons. J Neurosci 28:862-867. 
 
26. de Calignon A, Spires-Jones TL, Pitstick R, Carlson GA, Hyman BT. (2009) Tanglebearing neurons survive 
despite disruption of membrane integrity in a mouse model of tauopathy. J Neuropathol Exp Neurol 68:757-761. 
 
27. Li M, Ona VO, Guegan C, et al. (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse 
model (see comments). Science 288:335-339. 
 
28. Ona VO, Li M, Vonsattel JP, et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of 
Huntington's disease. Nature 399:263-267. 
 
29. Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. (1999) Caspase inhibition reduces 
apoptosis and increases survival of nigral transplants. Nat Med 5:97-100. 
 
30. Friedlander RM. (2003) Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348:1365-1375. 
 
31. Van Noorden CJ. (2001) The history of Z-VAD-FMK, a tool for understanding the significance of caspase 
inhibition. Acta Histochem 103:241-251. 
 
32. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. (2003) Q-VD-OPh, a broad spectrum caspase 
inhibitor with potent antiapoptotic properties. Apoptosis 8:345-352. 
 
33. Chauvier D, Ankri S, Charriaut-Marlangue C, Casimir R, Jacotot E. (2007) Broad-spectrum caspase inhibitors: 
from myth to reality? Cell Death Differ 14:387-391. 
 
34. Yang L, Sugama S, Mischak RP, et al. (2004) A novel systemically active caspase inhibitor attenuates the 
toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis 17:250-259. 
 
35. Braun JS, Prass K, Dirnagl U, Meisel A, Meisel C. (2007) Protection from brain damage and bacterial infection 
in murine stroke by the novel caspase-inhibitor Q-VD-OPH. Exp Neurol 206:183-191. 
 
36. Kim HS, Suh YH. (2009) Minocycline and neurodegenerative diseases. Behav Brain Res 196:168-179. 
6
 
 
This is an author-produced, peer-reviewed version of this article.  The final publication is available at www.springerlink.com. Copyright 
restrictions may apply.  DOI: 10.1007/s10495-010-0463-2 
 
37. Gordon PH, Moore DH, Miller RG, et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral 
sclerosis: a phase III randomised trial. Lancet Neurol 6:1045-1053. 
 
38. Choi Y, Kim HS, Shin KY, et al. (2007) Minocycline Attenuates Neuronal Cell Death and Improves Cognitive 
Impairment in Alzheimer's Disease Models. Neuropsychopharmacology. 
 
39. Fan R, Xu F, Previti ML, et al. (2007) Minocycline reduces microglial activation and improves behavioral 
deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci 27:3057-3063. 
 
40. Seabrook TJ, Jiang L, Maier M, Lemere CA. (2006) Minocycline affects microglia activation, Abeta deposition, 
and behavior in APP-tg mice. Glia 53:776-782. 
 
41. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. (2009) Minocycline reduces the 
development of abnormal tau species in models of Alzheimer's disease. Faseb J 23:739-750. 
 
42. Zhu S, Stavrovskaya IG, Drozda M, et al. (2002) Minocycline inhibits cytochrome c release and delays 
progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78. 
 
43. Teng YD, Choi H, Onario RC, et al. (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome 
c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 101:3071-3076. 
 
44. Tikka TM, Koistinaho JE. (2001) Minocycline provides neuroprotection against Nmethyl- D-aspartate 
neurotoxicity by inhibiting microglia. J Immunol 166:7527-7533. 
 
45. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. (2001) Minocycline, a tetracycline derivative, is 
neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580-
2588. 
 
46. Streit WJ. (2005) Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Brain Res Rev 
48:234-239. 
 
47. Pockros PJ, Schiff ER, Shiffman ML, et al. (2007) Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower 
aminotransferase activity in patients with chronic hepatitis C. Hepatology 46:324-329.  
 
48. Investigators NN-P. (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-
month results. Clin Neuropharmacol 31:141-150. 
 
49. Frisoni GB, Delacourte A. (2009) Neuroimaging outcomes in clinical trials in Alzheimer's disease. J Nutr Health 
Aging 13:209-212. 
 
50. Butterfield DA. (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for 
neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36:1307-1313. 
 
51. Smith DG, Cappai R, Barnham KJ. (2007) The redox chemistry of the Alzheimer's 
disease amyloid beta peptide. Biochim Biophys Acta 1768:1976-1990. 
 
 
 
 
 
 
 
 
 
 
7
 
 
This is an author-produced, peer-reviewed version of this article.  The final publication is available at www.springerlink.com. Copyright 
restrictions may apply.  DOI: 10.1007/s10495-010-0463-2 
Table 1. Comparisons of Q-VD-OPh and minocycline as potential compounds for the treatment of 
Alzheimer’s disease 
 
Compound Mechanism of  
Action 
Advantages Disadvantages 
Q-VD-OPh Broad pan-caspase inhibitor 
with no cross-reactivity to 
other proteases including 
cathepsins, calpains, or 
granzyme B. 
Proven caspase inhibitor with 
very select mechanism of 
action. Great improvements 
over older compounds such as 
Z-VAD including potency, 
toxicity, and stability. 
Transport into the CNS, 
bioavailability, and 
selectivity for specific 
caspases could be 
problematic. Selection 
between “good” versus 
“bad” apoptosis. Cost 
prohibitive for long-term 
study (3-24 months). Little 
in vivo data available  
compared to minocycline. 
Minocycline 1) Anti-apoptotic actions; 
both caspase-dependent and 
independent 
2) Anti-inflammatory 
actions; suppression of 
microglia and inhibition of T 
lymphocytes 
3) Inhibition of p38 MAPK 
activation in microglia 
Orally available and 
demonstrated effectiveness in a 
number of other model 
degenerative diseases. Proven 
tract record for safety in 
humans. Potential dual 
functions as apoptotic inhibitor 
and anti-inflammatory agent 
may beneficial in treating AD. 
Limited testing in animal 
models of AD. 
Multiplicity of actions 
may lead to untoward 
side effects. Recent ALS 
Phase III clinical trial with 
minocycline was negative. 
Clinical trials in PD and 
Huntington’s disease have 
revealed potential safety 
concerns in humans. 
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Figure Legends 
 
Fig. 1 Senile plaques and neurofibrillary tangles are the hallmarks of Alzheimer’s disease 
Representative staining from an age-matched control subject (a) or an individual with severe AD (b). In AD, 
widespread labeling of senile plaques composed principally of the A  (brown staining) along with numerous 
NFTs composed of truncated and hyperphosphorylated tau (blue staining) can be seen in the entorhinal cortex. 
Often, one can observe a few NFTs along with neuropil threads in the absence of A -matched 
controls. However, the difference clearly being the number of NFTs observed as compared to the AD brain. 
 
Fig. 2 Putative pathway of NFT formation and neuronal cell death in Alzheimer’s disease. 
According to the A synthesis following cleavage by  APP molecule leads 
to all subsequent downstream events. In one scenario, A  oligomers leading to the production of 
reactive oxygen species (ROS), oxidative stress and eventually cell death [50, 51]. Alternatively or simultaneously, 
A  activation through the initiation of apoptosis. The activation of caspases leads to the 
cleavage of critical cellular proteins including actin, fodrin and most importantly tau. The cleavage of these proteins 
may result in the breakdown of the cytoskeleton while the cleavage of tau may facilitate its hyperphosphorylation, 
leading to further instability in the cytoskeleton. Disruption of the microtubule network may also lead to impaired 
axonal transport and eventually neuronal cell death. Not shown is the fact that caspases have also been shown to 
cleave APP and thus, facilitate the further production of A  
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